

# Ou Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1543722/publications.pdf>

Version: 2024-02-01

61  
papers

998  
citations

567281

15  
h-index

477307

29  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1806  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e147-e156.	2.4	1
2	ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis. <i>BMC Cancer</i> , 2022, 22, 226.	2.6	7
3	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age. <i>Journal of Translational Medicine</i> , 2021, 19, 75.	4.4	3
4	Abstract PS17-38: Comprehensive association analysis of 21-gene recurrence score and overweight in breast cancer patients. , 2021, , .		0
5	Abstract PS18-22: Association of molecular biomarkers heterogeneity and treatment pattern, disease outcomes in multifocal or multicentric breast cancer patients. , 2021, , .		0
6	Abstract PS4-28: Efficacy of adjuvant chemotherapy stratified by age and the 21 gene recurrence score in estrogen receptor positive breast cancer. , 2021, , .		0
7	Abstract PS9-10: Can composite risk model help clinicians make adjuvant ovary function suppression decision for breast cancer patients. , 2021, , .		0
8	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 619840.	2.8	5
9	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2021, 21, 707.	2.6	1
10	Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients. <i>BMC Cancer</i> , 2021, 21, 807.	2.6	1
11	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27576.	4.3	13
12	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. <i>American Journal of Cancer Research</i> , 2021, 11, 6188-6199.	1.4	0
13	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. <i>BMC Cancer</i> , 2020, 20, 663.	2.6	13
14	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. <i>Breast</i> , 2020, 54, 235-241.	2.2	10
15	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1315.	2.8	3
16	<p>Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8027-8036.	2.0	5
17	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1335.	2.8	2
18	Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1384.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. <i>Journal of Cancer</i> , 2020, 11, 6916-6924.	2.5	8
20	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 708.	2.8	2
21	Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 2602-2609.	2.5	0
22	Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort. <i>Hypertension</i> , 2020, 75, 772-780.	2.7	48
23	IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 550.	2.8	11
24	Long noncoding RNA Inc-LOC645166 promotes adriamycin resistance via NF- $\kappa$ B/GATA3 axis in breast cancer. <i>Aging</i> , 2020, 12, 8893-8912.	3.1	16
25	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of $\geq 30$ . <i>Oncology Letters</i> , 2020, 20, 1545-1556.	1.8	4
26	Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study. <i>Cancer Research and Treatment</i> , 2020, 52, 671-679.	3.0	5
27	Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients. <i>Oncology Letters</i> , 2019, 18, 742-750.	1.8	5
28	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. <i>Scientific Reports</i> , 2019, 9, 13123.	3.3	13
29	Effect of titanium implants with coatings of different pore sizes on adhesion and osteogenic differentiation of BMSCs. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 290-299.	2.8	22
30	A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab. <i>Cancer Management and Research</i> , 2019, Volume 11, 3371-3379.	1.9	13
31	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. <i>Annals of Surgical Oncology</i> , 2019, 26, 2779-2786.	1.5	13
32	Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3977-3989.	2.0	19
33	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1877-1886.	2.5	21
34	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. <i>Journal of Cancer</i> , 2019, 10, 1110-1116.	2.5	9
35	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. <i>World Journal of Surgical Oncology</i> , 2019, 17, 37.	1.9	18
36	BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer. <i>Oncology Letters</i> , 2019, 18, 4992-5001.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Preoperative Axillary Ultrasound in the Selection of Patients With a Heavy Axillary Tumor Burden in Early-Stage Breast Cancer: What Leads to False-Positive Results?. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 1357-1365.	1.7	15
38	Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. <i>European Journal of Cancer</i> , 2018, 89, 9-18.	2.8	20
39	The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 11816-11823.	1.8	17
40	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. <i>Journal of Cancer</i> , 2018, 9, 3216-3224.	2.5	9
41	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 222-230.	2.2	5
42	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1874-1880.	1.5	6
43	Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 406-413.	2.0	14
44	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. <i>Oncotarget</i> , 2017, 8, 38706-38716.	1.8	31
45	Analysis of factors related to adjuvant chemotherapy decision in early breast cancer patients with intermediate recurrence score.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12032-e12032.	1.6	0
46	Axillary Staging of Early-Stage Invasive Breast Cancer by Ultrasound-Guided Fine-Needle Aspiration Cytology. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 885-893.	1.7	32
47	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152500.	2.5	219
48	Biologic behavior and long-term outcomes of breast ductal carcinoma <i>in situ</i> with microinvasion. <i>Oncotarget</i> , 2016, 7, 64182-64190.	1.8	34
49	Prognostic and predictive value of Ki-67 in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 31079-31087.	1.8	34
50	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 822.	2.6	34
51	Targeting rho guanine nucleotide exchange factor ARHGEF5/TIM with auto-inhibitory peptides in human breast cancer. <i>Amino Acids</i> , 2015, 47, 1239-1246.	2.7	10
52	Prognostic Factors of Survival in Pathologic Incomplete Response Patients with Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 1181-1190.	1.8	3
53	Fibrin-Sealant-Delivered Cisplatin Chemotherapy Versus Cisplatin Hyperthermic Intraperitoneal Perfusion Chemotherapy for Locally Advanced Gastric Cancer Without Peritoneal Metastases: A Randomized Phase-II Clinical Trial with a 40-Month Follow-up. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 1171-1180.	1.8	10
54	Featured Article: Terflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. <i>Experimental Biology and Medicine</i> , 2015, 240, 426-437.	2.4	42

#	ARTICLE	IF	CITATIONS
55	A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. <i>Oncology Reports</i> , 2014, 32, 627-634.	2.6	6
56	Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. <i>Molecular and Clinical Oncology</i> , 2014, 2, 997-1002.	1.0	4
57	FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 1089-1094.	1.8	0
58	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. <i>Biochemical Pharmacology</i> , 2014, 87, 254-283.	4.4	100
59	Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 1064-1072.	1.3	6
60	Sentinel lymph node biopsy is unsuitable for routine practice in younger female patients with unilateral low-risk papillary thyroid carcinoma. <i>BMC Cancer</i> , 2011, 11, 386.	2.6	26
61	Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. <i>BMC Cancer</i> , 2009, 9, 375.	2.6	10